29 results on '"Pan, Ling"'
Search Results
2. Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia
3. A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy
4. Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor
5. Is the 2nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study
6. Earlier Use of Zanubrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Is Associated with Greater Efficacy: A Pooled Analysis from 3 Studies
7. The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 109/L to < 100 × 109/L) at Baseline
8. Efficacy Analysis of Ruxolitinib in Treatment of 72 Patients with Myelofibrosis in a Chinese Institution
9. Onset of Regulatory B Cells Occurs at Initial Stage of B Cell Dysfunction in Multiple Myeloma
10. Is the 2ndGeneration Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study
11. A predictive model for therapy failure in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy
12. The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 109/L to < 100 × 109/L) at Baseline
13. Retrospective Treatment Analysis of a Series of 104 Patients with Adult Onset Hemophagocytic Lymphohistiocytosis in a Single Institution of China
14. A Predictive Scoring System for Therapy Failure of Tyrosine-Kinase Inhibitors in Patients with Chronic-Phase Chronic Myeloid Leukemia
15. First-in-Class JAK/Rock Inhibitor Rovadicitinib in Myeloproliferative Neoplasms: A Single Arm, Multicenter, Open-Label, Phase I/Ib Study
16. 4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass
17. Transiently Elevated AST/LDH Are Associated with Clinical Response to Recombinant Circularly Permuted TRAIL (CPT) Plus Thalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma
18. This Is a Title In Title Case: Safety and Efficacy of Intravenous 4.5g/m2 Methotrexate over 90 Minutes for Hematological Malignancy with Cerebral Involvement
19. Decitabine Combined With Chemotherapy For The Treatment Of Refractory Acute Myeloid Leukemia: a Pilot Phase 1 Clinical Study
20. Recombinant Circularly Permuted TRAIL (CPT) for the Treatment of Relapsed or Refractory Multiple Myeloma: An Open-Label, Multicenter Phase II Clinical Trial
21. Sfrps Family Invovled in Growth Inhibition of K562 Cells Induced by Artesunate
22. Effect of Artesunate On Inhibiting Proliferation and Inducing Apoptosis of SP2/0 Myeloma Cells through Affecting NFκB p65.
23. Effects of rmhTRAIL Combined with Daunorubicin in Inducing Apoptosis of Leukemia Cell Lines and Its Mechanism.
24. Expression and Mutation Analysis of the Myc Antagonist Gene Mad1 in Acute Leukemia.
25. Preclinical Research on Idiotype Vaccine Against B Cell Lymphoma.
26. Effects of Integrin α5β1-Mediated Signal TransductionPathways on the Proliferation and Apoptosis of K562 and CML Cells.
27. In Vivo Phycocyanin Treatment of S180 Bearing-Mice: Increase in Immunic Function and Inhibition of Tumor Growth.
28. Establishment of a Retroviral Mouse Model for inv(16)-Mediated Acute Myeloid Leukemia Suggests That the p14ARF Tumor Suppressor Is a Transcriptional Target for Repression by the inv(16) Fusion Protein.
29. Establishment of a Retroviral Mouse Model for inv(16)-Mediated Acute Myeloid Leukemia Suggests That the p14ARFTumor Suppressor Is a Transcriptional Target for Repression by the inv(16) Fusion Protein.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.